Tenet Healthcare Corporation (THC) Market Cap

Tenet Healthcare Corporation (THC) has a market capitalization of $20.74B, based on the latest available market data.

Financials updated after earnings reported 2025-12-31.

Sector: Healthcare
Industry: Medical - Care Facilities
Employees: 98000
Exchange: New York Stock Exchange
Headquarters: Dallas, TX, US
Website: https://www.tenethealth.com

Loading company profile...

Expand full investment commentary ▼

📘 TENET HEALTHCARE CORP (THC) — Investment Overview

🧩 Business Model Overview

Tenet Healthcare Corporation (THC) operates as a diversified healthcare services company in the United States. Its core businesses span hospital operations, ambulatory surgery centers (ASCs), and revenue cycle management solutions. Through its subsidiaries, Tenet owns, leases, and operates acute care hospitals, surgical hospitals, outpatient centers, and provides related healthcare services. The company’s business model hinges on delivering acute and specialty care through its network, capturing patient volumes, and leveraging operational efficiencies to drive both top-line growth and profitability. Tenet’s structure is organized around three main segments: Hospital Operations, United Surgical Partners International (USPI - ASCs and surgical facilities), and Conifer Health Solutions (third-party revenue cycle management). This mix enables flexibility, geographic diversification, and exposure to multiple reimbursement streams across the healthcare continuum.

💰 Revenue Streams & Monetisation Model

Tenet generates revenue predominantly from patient services within its hospitals and ambulatory facilities. Its revenue mix is diversified as follows: - **Hospital Operations:** This segment includes acute care services, specialty care, and emergency services. Hospitals are reimbursed via government programs (Medicare, Medicaid), commercial insurers, and self-pay patients. - **Ambulatory Care (USPI):** USPI manages and owns ambulatory surgery centers and surgical hospitals. Revenue is driven by high-margin outpatient procedures, partnering with physicians, and network agreements with health plans. - **Conifer Health Solutions:** Conifer provides revenue cycle management and value-based care solutions to hospitals and physician groups. This business operates under long-term contracts, generating predictable fee-based revenues. This multifaceted approach reduces reliance on any single payer or segment, helping to temper cyclical or regulatory risks in healthcare reimbursement.

🧠 Competitive Advantages & Market Positioning

Tenet’s competitive position stems from operational scale, service diversification, and focused investments in high-growth ambulatory services. Key differentiators include: - **Extensive National Footprint:** With a broad geographic presence, Tenet can leverage scale in procurement, technology investments, and administrative processes. - **Leading Position in Ambulatory Services:** Through the USPI platform, Tenet is one of the largest ASC operators in the country, benefiting from the secular shift toward outpatient care. - **Physician Alignment:** Joint venture partnerships with physicians in many markets foster alignment, referral stream stability, and clinician engagement. - **Integrated Care Delivery:** The combination of hospitals, outpatient centers, and revenue cycle services supports seamless patient care transitions and administrative efficiency. - **Revenue Cycle Expertise:** Via Conifer, Tenet maintains a strong capability in optimizing collections, billing, and compliance for both internal operations and external clients. These strengths position Tenet to compete effectively against both national hospital chains and regional healthcare providers.

🚀 Multi-Year Growth Drivers

Tenet’s long-term growth is underpinned by several key secular and company-specific drivers: - **Expansion of Ambulatory Surgical Centers:** The healthcare industry is experiencing a migration of procedures from inpatient to lower-cost outpatient settings. Tenet’s early and substantial investments in ASCs via USPI position it for sustained volume and margin growth. - **Aging Population and Chronic Disease Prevalence:** Demographic trends are fueling demand for both acute and elective healthcare services, supporting volume growth across Tenet’s markets. - **Strategic Capital Allocation:** Tenet has demonstrated a disciplined approach to capital deployment — including selective acquisitions, divestitures of non-core assets, and targeted hospital investments in growing geographies. - **Operational Efficiencies and Margin Improvement:** Ongoing efforts to enhance clinical operations, streamline administration, and leverage digital technology support cost management and incremental margin expansion. - **Value-Based Care Evolution:** The healthcare payment landscape is increasingly rewarding value and outcomes over volume. Tenet’s experience with risk-based contracts through Conifer aligns with evolving payer dynamics. Collectively, these factors drive a multi-year expansion opportunity across Tenet’s diversified business lines.

⚠ Risk Factors to Monitor

Investing in Tenet entails several notable risks: - **Regulatory and Reimbursement Pressure:** Changes in government reimbursement (Medicare/Medicaid), commercial payer negotiations, or regulatory reforms can impact revenue and margins. - **Competition and Physician Dynamics:** Increased competition for patient volume and physician referrals, as well as potential changes in clinician alignment, may affect market share and pricing power. - **Debt and Leverage:** Tenet has historically operated with significant financial leverage, obliging strict discipline in balance sheet management. - **Operational Disruptions:** Staffing shortages, cybersecurity threats, and periods of lower patient volumes (such as during health crises) may negatively affect operations. - **Litigation and Compliance:** As with most large healthcare providers, Tenet faces periodic legal, regulatory, and compliance risks inherent to the industry. Monitoring these factors is critical to assessing the sustainability of Tenet’s business and long-term financial profile.

📊 Valuation & Market View

Tenet’s valuation is commonly assessed using forward EBITDA multiples and comparative peer group analysis (e.g., relative to other large hospital operators and ASC providers). The company’s profile includes higher margins due to its ambulatory mix, balanced by its leverage and hospital exposure. Market participants evaluate Tenet for: - Growth prospects in outpatient and value-based care. - Track record of capital allocation, including debt reduction and share repurchase activity. - Execution on margin expansion and asset portfolio optimization. - Sensitivity analysis based on macroeconomic or regulatory headwinds. Relative to peers, Tenet may command a premium for its USPI exposure, though valuation is tempered by its legacy hospital business and leverage.

🔍 Investment Takeaway

Tenet Healthcare represents a leading hybrid platform in U.S. healthcare, blending scale in acute care with strategic leadership in ambulatory surgery and revenue cycle management. The company is positioned to benefit from favorable demographic trends, an industry shift toward outpatient services, and margin-enhancing operational priorities. Its diversified model offers resilience across multiple payer and service lines. Nevertheless, the investment profile is shaped by high financial leverage, ongoing regulatory uncertainty, and inherent competitive pressures in healthcare delivery. For investors seeking exposure to structural healthcare growth themes with a willingness to monitor risk factors, Tenet Healthcare provides a compelling, albeit levered, opportunity set within the sector.

⚠ AI-generated — informational only. Validate using filings before investing.

📢 Show latest earnings summary

THC Q4 2025 Earnings Summary

Overall summary: Tenet delivered strong Q4 and full-year 2025 results with double-digit EBITDA growth, widening margins, and robust free cash flow. USPI and the Hospital segment both outperformed, supported by high acuity, favorable mix, and tight cost control. 2026 guidance points to continued growth, aided by USPI expansion and structural cost initiatives, but tempered by a sizable headwind from the expiration of enhanced ACA exchange tax credits. Management remains confident, highlighting healthy pipelines, strong liquidity, and disciplined capital deployment, while acknowledging payer-mix uncertainty in 2026.

Growth

  • 2025 consolidated adjusted EBITDA $4.566B, up 14% YoY; margin 21.4% (+210 bps)
  • Q4 2025 adjusted EBITDA $1.183B, up 13% YoY; margin 21.4%
  • USPI 2025 adjusted EBITDA $2.026B, up 12% YoY; same-facility revenue +7.5%
  • USPI Q4 same-facility revenue +7.2% YoY; net revenue/case +5.5%; case volumes +1.6%
  • Hospital segment 2025 adjusted EBITDA $2.54B, up 16% YoY; same-store revenue/adjusted admission +5.3%
  • Hospital Q4 revenue/adjusted admission +7.5% YoY; inpatient adjusted admissions flat

Business development

  • Added 35 USPI facilities in 2025 via M&A and de novo; ~$350M invested
  • Strong 2026 pipeline; targeting ~$250M USPI M&A spend
  • Phase-out of inpatient-only list starting 2026 expected to shift more cases to ASCs (spine, urology focus)
  • Physician recruitment and service-line expansion underway across hospitals and USPI
  • Conifer transaction completed; one-time $40M favorable revenue adjustment to be recognized in 2026

Financials

  • 2025 net operating revenues $21.3B
  • Q4 2025 net operating revenues $5.5B
  • Salary, wages & benefits 40.2% of Q4 net revenue (−110 bps YoY); contract labor 2.1% of SW&D
  • Free cash flow: $367M in Q4; $2.53B for 2025
  • 2025 adjusted EBITDA ended nearly $500M above initial midpoint guidance
  • Normalizing items: $148M prior-year supplemental Medicaid in 2025; +$40M one-time Conifer revenue in 2026

Capital & funding

  • Cash on hand $2.88B at 12/31/25; no revolver borrowings
  • No significant debt maturities until late 2027
  • Leverage 2.25x EBITDA (2.85x EBITDA less NCI)
  • Share repurchases: 943k shares/$198M in Q4; 8.8M shares/$1.386B in 2025; ~22% of shares retired since 2022 (~$2.5B)
  • 2026 cash flow outlook: CFO $3.2B–$3.6B; capex $700M–$800M; FCF $2.5B–$2.8B; FCF after NCI $1.6B–$1.83B (includes ~$150M Conifer taxes)

Operations & strategy

  • Shifting more procedures to lower-cost ASCs; USPI positioned as preferred acquirer/developer
  • Structural expense management via technology, automation, and Global Business Center
  • Operational initiatives in clinical throughput (length of stay, OR/ER flow) to enhance capacity and margins
  • Continued investment in higher-acuity hospital service lines
  • Disciplined cost controls and efficiency programs embedded in 2026 plans

Market & outlook

  • 2026 guidance: consolidated net revenue $21.5B–$22.3B; adjusted EBITDA $4.485B–$4.785B
  • USPI 2026 adjusted EBITDA $2.13B–$2.23B; same-facility revenue growth 3%–6%
  • Hospitals 2026 adjusted EBITDA $2.355B–$2.555B; same-hospital admissions growth 1%–2%
  • Q1 2026 seasonality: ~24% of full-year consolidated EBITDA; USPI ~22% of its full-year
  • Excludes potential upside from unapproved supplemental Medicaid programs
  • After normalizing items and excluding exchange headwind, 2026 EBITDA growth expected ~10% at midpoint

Risks & headwinds

  • Expiration of enhanced ACA exchange premium tax credits; assumed 20% enrollment reduction (AZ, MI, CA exposure)
  • ~$250M estimated 2026 EBITDA headwind from exchange changes, primarily in hospitals
  • Uncertainty in exchange effectuation rates and potential rise in uninsured mix
  • Weaker-than-expected respiratory/flu season impacted certain Q4 hospital volumes
  • Regulatory/timing uncertainty around supplemental Medicaid program approvals

Sentiment: mixed

📊 Tenet Healthcare Corporation (THC) — AI Scoring Summary

📊 AI Stock Rating — Summary

Tenet Healthcare Corporation reported a revenue of $5.53 billion and a net income of $371 million for the quarter ending December 31, 2025. The earnings per share (EPS) stood at $4.25, reflecting solid profitability metrics with a notable net margin of 6.71%. Free cash flow was robust at $367 million, demonstrating strong cash generation capabilities. Year-over-year growth in revenue suggests stable business operations, supported by efficient cost management. With total assets of approximately $29.68 billion against total liabilities of $20.70 billion, the company maintains a healthy balance sheet. The net debt position of $10.29 billion requires monitoring, although operating cash flows provide a firm footing. The company has not paid dividends recently but has engaged in stock repurchases amounting to $202 million, signaling a focus on enhancing shareholder value through buybacks. The analyst price target consensus of $240.45 indicates positive sentiment. Overall, Tenet’s performance is strong, underpinned by solid revenue growth and cash flow management, while its leverage is reasonable given its operating metrics.

AI Score Breakdown

Revenue Growth — Score: 8/10

The year-over-year revenue growth stands robust, indicating stable operations. Continued focus on expanding service offerings contributes as a main driver.

Profitability — Score: 8/10

The company demonstrates strong profitability with a net margin of 6.71% and an EPS of $4.25, suggesting efficient operations and cost management.

Cash Flow Quality — Score: 7/10

Free cash flow is stable at $367M. No dividends, but a significant buyback program enhances shareholder value. Cash reserves seem adequate.

Leverage & Balance Sheet — Score: 7/10

Net debt is considerable at $10.29B, but a strong asset base and cash flow provide resilience. Leverage needs monitoring.

Shareholder Returns — Score: 8/10

Shareholder returns boosted through buybacks over dividends, reinforcing value creation strategy. Positive analyst sentiment offers additional support.

Analyst Sentiment & Valuation — Score: 8/10

Valuation metrics suggest the stock is reasonably priced with an analyst consensus target of $240.45. Market sentiment remains favorable.

⚠ AI-generated — informational only, not financial advice.

SEC Filings

Related Companies in Healthcare

ROIV logo

ROIVANT SCIENCES LTD (ROIV)

Healthcare

$20.71B

ILMN logo

ILLUMINA INC (ILMN)

Healthcare

$20.56B

MRNA logo

MODERNA INC (MRNA)

Healthcare

$20.93B

INCY logo

INCYTE CORP (INCY)

Healthcare

$20.15B

RPRX logo

ROYALTY PHARMA PLC CLASS A (RPRX)

Healthcare

$19.80B

EXAS logo

EXACT SCIENCES CORP (EXAS)

Healthcare

$19.73B